Montréal, Québec
Canada
Report ASL-2027-000418 · Issued 14 April 2027 · Page 1 of 2
| Analysis | Method | Result | Spec |
|---|---|---|---|
| Identity | LC-MS (ESI+) | m/z 1419.5 [M+H]⁺ Theoretical 1419.5 | Pass |
| Purity | RP-HPLC-UV 214 nm | 98.7% Area normalisation | Pass |
| Net content | Quantitative HPLC | 5.02 mg / vial Labelled 5 mg | Pass |
| Water content | Karl Fischer | 4.1% | Pass |
| Bacterial endotoxins | USP <85> kinetic chromogenic | <0.05 EU/mg | Pass |
| Appearance | Visual | White lyophilised cake | Pass |
Photographed at accessioning, before any vial was opened.
Purity by reversed-phase HPLC, C18 4.6 × 250 mm 5 µm, gradient 5–65% acetonitrile in 0.1% TFA over 30 min, 1.0 mL/min, UV detection at 214 nm, reported by area normalisation with all impurities ≥0.05% listed on page 2. Identity by electrospray-ionisation mass spectrometry in positive mode. Net content by quantitative HPLC against a certified reference standard, three replicate injections. Water content by coulometric Karl Fischer titration. Endotoxins by kinetic chromogenic LAL to USP <85>, sensitivity 0.005 EU/mL. Analysis performed at the Axiom Bio Labs facility, Montréal, Québec.
This certificate applies only to the sample submitted, as received, on the dates stated. It is not a marketing authorisation, health product licence, DIN, NPN or FDA clearance, and makes no statement of safety, efficacy or fitness for any purpose. Results are for research and quality-control use only. Verify this certificate at axiombiolabsinc.com/verify using access code AXK7QD3W.
Analytical Chemist, Axiom Bio Labs
Released 14 April 2027 · Access code AXK7QD3W